National Bank of Canada
CTXR icon

National Bank of Canada’s Citius Pharmaceuticals CTXR Stock Holding History

National Bank of Canada’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-185
Closed -$5.51K – 2805
2023
Q2 		$5.51K Hold
185
– – ﹤0.01% 2319
2023
Q1 		$5.37K Buy
+185
New +$5.33K ﹤0.01% 2269

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

National Bank of Canada's CTXR Position: Q3 2023 in Review

National Bank of Canada sold out of Citius Pharmaceuticals (CTXR) in Q3 2023, closing a stake of 185 shares — an estimated $5.51K sold.

National Bank of Canada first reported a position in CTXR in Q1 2023 and held it in 2 quarters. The position peaked at $5.51K in Q2 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q3 2023.

  • National Bank of Canada reported no remaining Citius Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • National Bank of Canada sold 185 Citius Pharmaceuticals shares in Q3 2023, an estimated $5.51K.
  • National Bank of Canada first reported a position in Citius Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • National Bank of Canada's Citius Pharmaceuticals position peaked at $5.51K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2023.

Based on National Bank of Canada's 13F filing for Q3 2023, filed 10 Oct 2023.